During the past decade, Nashville Medical Research Institute conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 38 clinical trials were completed, i.e. on average, 90.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 24 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nashville Medical Research Institute" #1 sponsor was "Bristol-Myers Squibb" with 12 trials, followed by "Gilead Sciences" with 11 trials sponsored, "Abbott" with 4 trials sponsored, "Allergan" with 4 trials sponsored and "Bausch Health Americas, Inc." with 4 trials sponsored. Other sponsors include 45 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nashville Medical Research Institute" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Novo Nordisk A/S" with 2 trials as a collaborator, "Elan Pharmaceuticals" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Galapagos NV" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Nashville Medical Research Institute" are "Crohn's Disease" (14 trials), "Ulcerative Colitis" (13 trials), "Gastroparesis" (5 trials), "Hepatitis C" (5 trials) and "Nonalcoholic Steatohepatitis" (5 trials). Many other conditions were trialed in "Nashville Medical Research Institute" in a lesser frequency.

Most popular intervention types in "Nashville Medical Research Institute" are "Drug" (73 trials), "Biological" (9 trials), "Other" (6 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Ribavirin" (6 trials), "Daclatasvir" (5 trials), "Filgotinib" (4 trials) and "SEL" (4 trials). Other intervention names were less common.

The vast majority of trials in "Nashville Medical Research Institute" are 83 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Nashville Medical Research Institute". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 64 completed trials in Nashville Medical Research Institute, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Nashville Medical Research Institute, 4 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".